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A B S T R A C T
Acute cardiovascular events, due to rupture or erosion of an atherosclerotic plaque, represent the major cause of
morbidity and mortality in patients. Growing evidence suggests that plaque neovascularization is an important
contributor to plaque growth and instability. The vessels’ immaturity, with profound structural and functional
abnormalities, leads to recurrent intraplaque hemorrhage.
This review discusses new insights of atherosclerotic neovascularization, including the effects of leaky
neovessels on intraplaque hemorrhage, both in experimental models and humans. Furthermore, modalities for
in vivo imaging and therapeutic interventions to target plaque angiogenesis will be discussed.
1. Introduction
The majority of acute cardiovascular events in patients is caused by
occlusive thrombosis formed by rupture or erosion of an atherosclero-
tic plaque (Hansson et al., 2015). Despite improved insight into disease
pathogenesis and therapeutic options, additional treatment strategies
are required to block mechanisms involved in plaque destabilization.
Advanced atherosclerotic lesions are characterized by large necrotic
cores with thin fibrous caps, cholesterol deposits, inflammatory cells
and calcifications (Yahagi et al., 2016). Recent insights in the patho-
physiology of atherosclerotic lesions have shed new light on the
formation of unstable lesions. For instance, it has been shown that,
of the total number of foam cells a significant portion is derived from
smooth muscle cells (SMCs) rather than from macrophages (Chaabane
et al., 2014). Also the role of calcification is more clarified, it has been
shown that extended calcification can stabilize atherosclerotic plaques
(Imoto et al., 2005), whereas spotty micro-calcifications contribute to
plaque destabilization (Ehara et al., 2004; Ruiz et al., 2015; Hutcheson
et al., 2016). Furthermore, it is becoming more and more clear that
plaque angiogenesis and intraplaque hemorrhage (IPH) are important
contributors to unstable lesions (Michel et al., 2011; Haasdijk et al.,
2016). Plaque angiogenesis is a physiological response to the increased
oxygen demand in the plaque but can have adverse effects by
facilitating IPH and influx of inflammatory mediators (de Vries and
Quax, 2016).
This review focusses on plaque angiogenesis, the relation with
inflammatory mediators, and the subsequent effects of IPH on plaque
instability, both in experimental models and in humans. Moreover,
options to target plaque angiogenesis for imaging and therapeutic
purposes will be discussed.
2. Angiogenesis-driving processes
2.1. Hypoxia
The molecular mechanism regulating angiogenesis in atherosclero-
sis involves signaling pathways that are mainly driven by the lack of
oxygen (Sluimer and Daemen, 2009). Hypoxia occurs when oxygen
supply is decreased and or oxygen demand is increased. The ability to
sense and respond to changes in O2 concentration is a fundamental
feature of all nucleated cells. Cell survival in a hypoxic environment
leads to a general shut-down of energy-consuming transcription and
translation, with one major exception — the hypoxia-inducible factor
(HIF) pathway (Semenza, 2003; Pouyssegur et al., 2006).
Hypoxia promotes monocyte/ macrophage survival and oxLDL
uptake by macrophages (Roiniotis et al., 2009). It also enhances the
expression of matrix metalloproteases by a variety of cells in the plaque
contributing to the instability of the plaque (Nakano et al., 2005).
Furthermore, due to the hypoxic state of macrophages ATP depletion
occurs, causing cell death and expansion of the necrotic core leading to
a feedback cycle between plaque expansion and hypoxia. Fong et al. has
shown that exposure to hypoxia accelerates the plaque growth of ApoE
KO mice fed with a high cholesterol diet (Fong, 2015). In contrast,
when atherosclerosis prone mice were exposed to carbogen (95% O2,
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5% CO2) oxygenation, plaque growth was inhibited (Pouyssegur et al.,
2006). Sluimer et al. showed extensive hypoxia in the center of
advanced human carotid atherosclerotic plaques (Sluimer et al.,
2008). Pimonidazole, a hypoxia marker, was co-localized with CD68
positive macrophages, HIF1-α and VEGF expression, suggesting the
involvement of the HIF pathway in the regulation of human plaque
angiogenesis and lesion progression (Sluimer, Gasc et al., 2008).
HIF is a heterodimeric protein composed of α and β subunits. The α
chain confers oxygen regulation on the complex and its expression is
hypoxia-dependent and has three isoforms, HIF-1α, 2α and 3α of
which only HIF-1α and HIF-1β are widely expressed in normal tissues
(Tian et al., 1997; Wiesener et al., 1998; Pugh and Ratcliffe, 2003). The
beta chain (three isoforms) is constitutively expressed and works as an
aryl receptor nuclear translocator. Under normoxic conditions, the
synthesized HIF-1α is rapidly degraded and the co-activators are
blocked by oxygen-dependent enzymes; the prolyl-hydroxylases do-
main (PHD) enzymes (Lando et al., 2002a, 2002b). During hypoxia,
PHD activity is reduced, allowing the dimerization of HIF-1α and HIF-
1β (Lee et al., 2004; Lijkwan et al., 2014). This active complex binds to
DNA starting the transcription of downstream genes involved in
angiogenesis and inflammation (Ho et al., 2006).
HIF-1α mediates inflammation by promoting pro-inflammatory
cytokine expression (stromal cell-derived factor 1, VEGF-A) and
consequently inflammatory cell recruitment (Ramkhelawon et al.,
2013; Folco et al., 2014). Aarup et al. have shown that HIF-1α
expression also modulates the macrophage glycolytic pathway, by
increasing glucose uptake and glucose transporter 1 mRNA expression,
enhancing oxygen consumption. In addition, HIF-1α reduces the
mRNA expression of the major cholesterol transporters (Aarup et al.,
2016) and activates the lectin-like OxLDL receptor-1 scavenger recep-
tors that mediates oxLDL uptake in macrophages (Crucet et al., 2013),
leading to the expansion of the foam cell population. Interestingly,
hypoxia can also reduce macrophage migration, by mediating the
expression of retention molecules that stimulate their accumulation
and prevent egression from the plaque (Ramkhelawon et al., 2013).
Thus, hypoxia induced overexpression of HIF-1α not only regulates
plaque angiogenesis, but also has additional effects stimulating the
growth of atherosclerotic plaques.
Moreover, extensive crosstalk between HIF and nuclear factor-kB
(NF-κB), two important molecular players in atherosclerosis, has been
reported. They have common activating stimuli and share regulators
and targets (Palazon et al., 2014; D'Ignazio et al., 2016). Only the
canonical NF-κB pathway is sensitive to hypoxia, while both the
inhibitor of NF-κB subunit alpha (IKKα) and the inhibitor of NF-κB
subunit beta (IKKβ) can be hydroxylated by PHD (Cummins et al.,
2006; Oliver et al., 2009). Marsch et al. shows that PHD1 knockout
mice display a protective cardiovascular metabolic phenotype with
lower plasma cholesterol levels and glucose tolerance improvement
(Marsch et al., 2016). Furthermore, NF-κB has been shown to play a
role in basal and stimulated HIF-1α mRNA expression. The p50 and
p65 NF-κB subunits can bind to the HIF-1α promoter in response to
hypoxia and when these subunits are overexpressed, an increase in
HIF-1α mRNA levels and promoter activity is observed (van Uden
et al., 2008). The full mechanism between HIF and NF-κB in hypoxia is
not yet completely understood but these features highlight the complex
and interrelated hypoxia and inflammatory signaling cascades in
atherosclerosis.
2.2. Endothelial cell sprouting
Angiogenic sprouting involves the invasion of avascular areas by
proliferating and migrating ECs. The mechanism of angiogenesis has
been deeply studied and the process of neovessel formation has been
described in detail (Carmeliet and Jain, 2011; Eelen et al., 2013;
Cantelmo et al., 2015; Coulon et al., 2010). In a nascent sprout, three
phenotypically distinct EC types can be recognized: tip, stalk and
phalanx cells. Tip cells are motile and invasive, protrude filopodia and
lead the way to the nascent sprout since they are located at the
forefront of the vessel branches, sensing and responding to guidance
cues in the microenvironment, while migrating toward an angiogenic
stimulus. Stalk cells trail behind the tip cells and elongate the stalk of
the sprout. These cells proliferate, form junctions, lay down extra-
cellular matrix and form a lumen. Phalanx cells are the most quiescent
ECs, lining vessels once the new vessel branches have been consoli-
dated (De Smet et al., 2009).
The differentiation of tip versus stalk cell occurs via a Notch
mediated lateral inhibition mechanism. VEGF-A and VEGF receptor
2 (VEGFR-2) signaling induces tip cells formation and delta-like
canonical Notch ligand 4 (Dll4) upregulation. Expression of Dll4 in
tip cells activates Notch in adjacent ECs, thereby decreasing the
expression of VEGFR-2 and inducing stalk cell differentiation
(Herbert and Stainier, 2011). Interestingly, it was shown that Notch
signaling promotes the progression of atherosclerosis in vivo (Herbert
and Stainier, 2011). Blockade of Dll4–Notch signaling by anti-Dll4
antibody administration, suppresses atheroma progression in the aorta
of LDLR KO mice that were fed high-cholesterol/high-fat diet for 24
weeks. Blockade of this angiogenesis related pathway leads to a
reduction in the accumulation of macrophages in the aorta of the mice
treated with neutralizing anti-Dll4 antibody (Herbert and Stainier,
2011), showing the tight interaction of these processes.
VEGF-A, VEGF-C and their receptors VEGFR-2 and VEGFR-3
participate in the detachment process of ECs from the ECM and guide
the behavioral switching of ECs. To ensure optimal fitness of the tip cell
leading the sprout, the EC with the highest responsiveness to VEGF will
occupy the tip position. Chronic inflammatory cell infiltration in the
atherosclerotic plaque activates ECs and enhances the expression of
different cell adhesion molecules like vascular cell adhesion protein 1
(VCAM-1) and intercellular Adhesion Molecule 1 (ICAM-1), which
recruit monocytes and lymphocytes (Van der Veken et al., 2016).
A stabilized and mature vascular plexus includes adoption of a
quiescent endothelial phalanx phenotype, branch regression, basement
membrane deposition and coverage with pericytes that will stabilize the
endothelial tubes and help regulating the capillary diameter and vessel
permeability. Fusion of sprouting neovessels, which is necessary to
form vascular networks, is controlled by bridging-macrophages
(Jaipersad et al., 2014). Macrophages accumulate at sites of vessel
anastomosis and interact with filopodia of neighboring tip cells during
fusion. It was shown in zebrafish embryos that macrophages can act as
cellular chaperones for endothelial cell fusion by bridging tip cells from
different vessel segments (Fantin et al., 2010).
Although it is widely accepted that angiogenesis is mainly regulated
by hypoxia, other factors like hemodynamic forces may also regulate
angiogenesis.
2.3. Hemodynamic forces
Blood flow plays crucial roles in angiogenesis by generating
frictional force that develops between flowing blood and the vascular
endothelium (Sewduth and Santoro, 2016). ECs covering the inner
surface of blood vessels are constantly exposed to different types of
shear stress. Shear stress is pulsatile in normal physiology, but can be
oscillatory in pathologies such as atherosclerosis, affecting endothelial
function and morphology. The EC response to shear stress is closely
linked to the regulation of vascular tone, blood coagulation and
fibrinolysis, angiogenesis, and vascular remodeling, and it plays an
important role in maintaining the homoeostasis of the circulatory
system (Ando and Yamamoto, 2013). Shear stress induces collateral
artery growth as well as capillary growth and it was shown that
endoglin played a crucial role in this process (Seghers et al., 2012).
Furthermore, it is known that shear stress modulates the expression of
thrombospondin 1 and its receptor CD36 during angiogenesis in vivo
(Bongrazio et al., 2006). Impairment of the EC is response to shear
L. Parma et al. European Journal of Pharmacology 816 (2017) 107–115
108
stress leads to activation of endothelial cells which ultimately can result
in vascular diseases such as hypertension, and atherosclerosis (Ando
and Yamamoto, 2013). The mechanisms and sensors by which ECs
initially recognize shear stress have yet to be confirmed, but the sensors
most likely involved in angiogenesis are Piezo1 (Li et al., 2014),
calcium (Qiu et al., 2001) and primary cilia (Goetz et al., 2014).
3. Angiogenesis in the atherosclerotic plaque
Pathological angiogenesis of the vessel wall is a consistent feature of
atherosclerotic plaque development and progression of the disease (van
Hinsbergh et al., 2015) however, the source of plaque neovessels is not
fully established. The general idea is that endothelial cells (ECs) grow
from the existing adventitial vasa vasorum triggered by a gradient of
VEGF. (Hellings et al., 2010).
Adventitial angiogenesis is thought to be the main source of
neovessels. In addition, it has been observed that angiogenesis also
occurs from the luminal side. However, clear evidence for the extent of
this phenomenon is lacking.
Due to its important role in atherosclerotic plaques, vasa vasorum
has been studied as a therapeutical target. Langheinrich et al. reported
a significant decrease of lesion size in ApoE LDL double KO mice
treated with 3-Deazaadenosine; an anti-inflammatory and anti-prolif-
erative drug. This was accompanied by a significant decrease of vasa
vasorum neovascularization, although no effects on intraplaque angio-
genesis were reported (Langheinrich et al., 2009).
Descriptive and cross-sectional studies in humans suggest a clear
association between the neovessel density and atherosclerotic progres-
sion and vulnerability (Sluimer and Daemen, 2009). A large long-
itudinal atherosclerosis plaque biobank study (AtheroExpress) demon-
strated that plaque neovascularization but also IPH significantly relate
to adverse cardiovascular outcome during clinical follow-up (Hellings
et al., 2010).
3.1. Intraplaque hemorrhage
Neovessels in vulnerable plaques are immature, irregular and
fragile due to the compromised structural integrity (J.Y. Xu et al.,
2015). In fact, they are characterized by a discontinuous basement
membrane and a low number of tight junctions between the ECs
(Sluimer et al., 2009). Moreover, these premature vessels are relatively
poor in pericyte coverage and are highly susceptible to the leakage of
circulating cells (Jeney et al., 2014) thus intraplaque hemorrhage
(IPH). In the oncology field, newly formed vessels in tumors have
been reported to have the same features. Tumor vessels are hetero-
geneous of appearance (J.A. Nagy et al., 2010), are organized in a
chaotic fashion and do not follow the hierarchical branching pattern of
normal vascular networks, seemingly lacking remodeling and pruning
(Jain, 2003). Many of these vessels are hyper-permeable (Nagy et al.,
2012). In their walls, there are inter-endothelial openings and trans-
endothelial channels, resulting in a wide range of pore sizes (Martin
et al., 2016). The hyper-permeability of tumor vessels allows plasma
and cells to leak to the interstitial space (Martin et al., 2016).
Of interest is that compared to normal individuals, patients with
acute coronary syndrome have red blood cells with higher amounts of
cholesterol in the membranes. Consequently the leakage of these red
blood cells may lead to an increased cholesterol deposition, atheroma
growth and decreasing plaque stability. Thus, the cholesterol content in
the red blood cell membrane could be a marker for the growth and
vulnerability of the atherosclerotic plaque (Giannoglou et al., 2009;
Tziakas et al., 2011). This is further illustrated below.
The key players in vessel maturation are VEGF its receptors and the
members of the angiopoietin system. VEGF and its main receptors
VEGFR-1 and VEGFR-2 drive EC proliferation and tube formation as
well as the attachment and detachment of pericytes during the
maturation of neovessels (Carmeliet and Jain, 2011). Angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) are ligands of the endothelial
receptor Tie-2, and both have a major role in the final maturation
phase of neovascularization with opposite functions. HIF-1α and
VEGF-A, induce Ang-2 to destabilize the interactions between pericytes
and ECs ECs, and thus allows vessels to grow. Ang-1 together with
platelet derived growth factor (PDGF) acts as a major stabilizing factor
that increases the stability of the junctions between the EC, thus
promoting vessel maturity and stability and reducing leakiness (Goel
et al., 2012). The balance between Ang-1 and Ang-2 expression was
explored in human plaques. A positive correlation was observed
between Ang-2 expression and microvascular density within the
plaque, as well as with the ratio Ang-2/Ang-1 (Post et al., 2008).
Also, PDGF-BB and its receptor (PDGFR)-β are known to be important
in vessel permeability, fragility, and impaired perfusion (Van der Veken
et al., 2016), due to their pivotal role of recruiting and stabilizing
perivascular cells.
These findings suggest that the neovessels are subjected to frequent
leakage in the form of extravasation of red blood cells, leucocytes and
plasma lipids to the surrounding tissue.
3.1.1. Red blood cells
Extravasated red blood cells (RBCs) constitute the main cellular
component of IPH, which with their hemoglobin content and cell
membrane components, enriched in unesterified cholesterol, partici-
pate in both the cholesterol accumulation and the oxidative process
(Michel et al., 2014). Once trapped in the highly oxidative environment
of the atherosclerotic plaques, RBCs tend to lyse quickly (E. Nagy et al.,
2010). The cytoplasm of RBCs is rich in hemoglobin, which can attract
multiple monocytes and neutrophils to the plaque (Jeney et al., 2014).
Cholesterol retention in the atherosclerotic plaque leads to choles-
terol crystal formation. This can originate directly from free cholesterol
or from cholesterol esters endocytosed by foam cells. RBC membranes
have a high cholesterol content with a percentage of lipids up to 40% of
the total weight of the cells (Kolodgie et al., 2007). It has been
suggested that RBC membranes are very important contributors to
lipid deposition and lipid core expansion upon IPH. This is further
illustrated by the presence of iron and glycophorin A, a characteristic
protein of the RBC membrane, which co-localizes with cholesterol
crystals within the plaques, suggesting that cholesterol crystals could
originate from erythrocytes phagocytized by macrophages (Kolodgie
et al., 2003).
3.2. Inflammation
Inflammation is a key factor in all stages of atherosclerosis
progression.
In the initial phase of atherosclerosis, oxidized low-density lipo-
proteins (oxLDL) accumulation in the aortic wall triggers the expres-
sion of adhesion molecules that facilitate the migration of monocytes
into the aortic wall (de Vries and Quax, 2016). Monocytes differentiate
into macrophages that engulf oxLDL and convert into lipid filled foam
cells. Accumulation of modified LDL by macrophages activates cyto-
kine production that on its turn, promote the influx and activation of
other inflammatory cells and their retention in the plaque. Most
inflammatory cells in the plaque, and especially macrophages, are
metabolic very active cells that exhibit high oxygen consumption which
leads to oxygen deprivation in the plaque (Marsch et al., 2013). In
addition, monocytes/macrophages release pro-angiogenic factors such
as VEGF and by interacting with vascular smooth muscle cells (VSMC),
macrophages induce unbalanced synthesis of the extracellular matrix
(ECM) leading to secretion of VEGF by VSMC (Khurana et al., 2005).
In advanced lesions, neovessel leakage constitutes the main en-
trance for inflammatory cells. RBCs can facilitate the extravasation of
circulating inflammatory cells by increasing the numbers of rolling and
adhering monocytes by enhancing the force and/or the frequency of
collision of monocytes with the endothelium (Melder et al., 2000). Not
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only monocytes are increasingly found around neovessels, also neu-
trophils and mast cells were found to be associated with neovessels.
These cells can release their granular content rich in serine proteases
and matrix metalloproteases that can digest components of elastic
fibers (elastin) and of the basement membrane (collagen, laminin and
fibronectin) (Michel et al., 2014). This high proteolytic activity can
ultimately lead to fibrous cap thinning and plaque erosion (Leclercq
et al., 2007; Dorweiler et al., 2008). Furthermore, the influx and lysis of
RBCs drives a higher request of macrophage activity in order to
phagocytose the RBC remainders. In combination with the hampered
efferocytosis (phagocytosis of dying/dead cells) response in the athero-
sclerotic lesions causing an impaired clearance of these apoptotic cells
by lesional macrophages, this may explain why these macrophage
accumulate in the atherosclerotic necrotic core, and may potentiate
vascular inflammation (Schrijvers et al., 2005; Kojima et al., 2016).
Additionally, their ability to efferocytose, is defective. This malfunc-
tioning increases the inflammation state and reduces cholesterol efflux
contributing to necrotic core expansion and ultimately, the increase of
risk of plaque rupture (Tabas and Bornfeldt, 2016). Furthermore, in
endarterectomy samples obtained during surgery an accumulation of
mast cells was observed in neovessel-rich areas of atherosclerotic
plaques (Willems et al., 2013). Whereas, in animal experiments it
was demonstrated that mast cells situated near the newly formed
vessels contained fibroblast growth factor (FGF), a potent pro-angio-
genic factor (Lappalainen et al., 2004). In line with these reports, it is
observed that vasa vasorum vessel density in atherosclerotic lesions of
ApoE KO mice highly correlates with the occurrence of inflammatory
cells foci (Khurana et al., 2005; Eriksson, 2011; Rademakers et al.,
2013; Butoi et al., 2016).
4. Imaging of angiogenesis
The detection of patients with atherosclerotic plaques at risk is a
major challenge for the cardiovascular research field and led to the
development of invasive and non-invasive imaging technologies to
visualize the atheroma in detail. The significant investments in these
imaging technologies are not only justified by the need to early
diagnose patients with atherosclerosis but also by the development of
drug programs (Goncalves et al., 2015).
The most prominent imaging technologies are already used in
clinical studies and their value to identify crucial characteristics of
vulnerable plaques is undeniable (Taqueti et al., 2014). Plaque
angiogenesis is one of these features and its detection in vivo can
represent a step forward in diagnosis and follow up of atherosclerosis.
The most advanced technique in humans to visualize angiogenesis
is positron emission tomography, PET (Alie et al., 2014; Calcagno et al.,
2016; Perez-Medina et al., 2016). This high sensitive tool uses 18F-
fluorodeoxyglucose (FDG), a glucose analogue tracer. After intravenous
injection, 18F-FDG is taken up by cells that metabolize glucose, where it
becomes trapped after phosphorylation. Due to the high glycolytic rate
of endothelial cells, plaque neovascularization can be monitored by
18F-FDG uptake (Taqueti et al., 2014). However, PET images do not
give structural information. This has to be assessed using PET with
combined techniques such as computed tomography (CT), magnetic
resonance imaging (MRI) (Magnoni et al., 2015). Another disadvan-
tage is the low resolution, as a result of this imaging of angiogenesis in
small size animal models is still a challenge.
Near-infrared fluorescence (NIRF) appears to be a highly versatile
platform for in vivo molecular imaging due to their picomolar
sensitivity and microscopic resolution (Bourantas et al., 2016a).
Matter et al. developed a sensor for NIRF that targets the extra-domain
B of fibronectin, inserted into fibronectin during angiogenesis. In this
study, blood vessels were visualized with a good target-to-background
ratio (Matter et al., 2004). NIRF can also be used for the identification
of specific plaque features, such as MMP activity (de Vries et al., 2012)
or flow patterns (Wong, et al., 2014; Wong et al., 2016). NIRF however
does not provide any structural information on the plaque. This
limitation can, in part, be overcome by multimodal imaging such as
NIRF–optical coherence tomography (OCT) and others (Wang et al.,
2015; Bourantas et al., 2016b).
OCT is an imaging technique also based on infrared light, which can
be used to study atherosclerotic plaques with extreme spatial accuracy.
OCT imaging presents a strong correlation to histology and specificity
to distinguish plaque phenotypes. OCT has been used to identify
patients with risk of plaque rupture by measuring calcified nodules,
fibrous cap thickness, lipid pool extension and also neovascularization
(Tsujita et al., 2016). However, contrary to PET and NIRF, OCT does
not allow specific molecular targeting.
No perfect technique is yet available but the combination of
multimodal technologies seems to be a promising opportunity for
imaging (Bourantas et al., 2016b). Furthermore, the strong correlation
between angiogenesis and plaque progression suggests a useful appli-
cation of imaging technologies as a therapeutic approach for patients
with atherosclerosis.
5. Angiogenesis targets
5.1. VEGF, Ang2 and Endostatin
In the last decade, there has been a substantial increase in
compounds targeting different pathways to counteract angiogenic
growth, mainly investigated in the oncological field. Interestingly,
lately more emphasis is put on stabilizing neovessels rather than
blockade of angiogenesis due to unwanted side effects (Goel et al.,
2012; Jain, 2014). Several approaches have been investigated in order
to block angiogenesis in the atherosclerotic plaques, such as the use of
anti-angiogenic agents and blocking pro-angiogenic factors.
Endostar is a novel modified recombinant human endostatin
(O'Reilly et al., 1997) a broad-spectrum angiogenesis inhibitor that
interferes with the pro-angiogenic action of growth factors such as
basic fibroblast growth factor (bFGF/FGF-2) and VEGF. A study in
ApoE KO mice showed that prolonged treatment with endostatin
reduced plaque growth (Moulton et al., 1999). More recently,
Endostar has been tested in a swine model (X. Xu et al., 2015). The
combination of hypercholesterolemic diet with balloon injury resulted
in early atherosclerotic lesions. The use of Endostar in this model
attenuates vasa vasorum neovascularization, vessel wall inflammation
and the progression of atherosclerosis.
A different therapeutic approach, besides the use of anti-angiogenic
agents, could be the blockade of pro-angiogenic factors.
Bevacizumab, a fully humanized anti-VEGF antibody is a well-
known inhibitor of angiogenesis and is widely used in clinical oncology.
Although Bevacizumab does not recognize murine VEGF (Bogdanovich
et al., 2016), it showed profound effects in a murine model by causing
disruption of the endothelium and consequently accelerated athero-
sclerosis in ApoE KO mice (Winnik et al., 2013).
In a New Zealand rabbits model, Bevacizumab-eluting stent
implantation in iliac arteries inhibits neovascularization without affect-
ing re-endothelialization. Local gene delivery of VEGFR-1 in the iliac
artery of a rabbit in which an atherosclerotic plaque was induced by
high-lipid diet in combination with balloon catheter injury, reduced
lesion formation. This occurred most likely via an inhibitory effect on
atherosclerotic plaque angiogenesis, which hints at the clinical utility of
sFlt-1 in atherosclerosis therapy (Wang et al., 2011).
Another angiogenic target under study is Ang-2. Blockade of Ang-2
on experimental atherosclerosis in LDLR-/- ApoB100/100 mice on high
cholesterol diet was shown to result in delayed fatty streak formation
and decreased plasma triglyceride levels. However, Ang-2 deletion did
not prevent plaque progression or changes in plaque stability and did
not affect adventitial neovessel density (Theelen et al., 2015).
So far, the ideal anti-angiogenic target in atherosclerosis is yet to be
found, but the potential of anti-angiogenic approaches in the tumor
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field, suggest that anti-angiogenic treatments in atherosclerosis will be
defined in the near future. Of note should be that targeting the vasa
vasorum neovascularization is a different approach than blocking the
intraplaque angiogenesis, despite the fact that the intraplaque angio-
genic capillaries have their origin in the vasa vasorum.
5.2. EC metabolism
In the field of (tumor) angiogenesis, it is well recognized that
endothelial cell metabolism changes during hypoxia, switching to
glycolysis-dependent ATP production (Cruys et al., 2016). In athero-
sclerosis, plaque progression is associated with macro and micro
endothelial dysfunction, which is attributed to EC metabolic maladap-
tation (Pircher et al., 2016). Therefore, targeting the endothelial
glycolytic metabolism might be a promising therapeutic approach. To
date, no treatments are available yet, however some targets have been
described: tetrahydrobiopterin (BH4), NADPH oxidase 1 (NOX1) and
NADPH oxidase 2 (NOX2) and 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 (PFKFB3) (Pircher et al., 2016).
BH4, an endothelial NOS (eNOS) cofactor, is metabolic inactivated
during endothelial dysfunction. Strategies to restore vascular BH4
availability is being tested in ongoing studies. In ApoE KO mice with
reduced nitric oxide (NO) synthesis, supplementation with BH4 pre-
cursors reduces reactive oxygen species (ROS) production and fosters
NO synthesis (Ozaki et al., 2002). However, clinical trials in patients
with coronary heart disease and myocardial infarction have shown
mixed results for BH4 supplementation (Bendall et al., 2014).
NOX enzymes are another important source of ROS in athero-
sclerosis which strongly affect plaque angiogenesis. NOX use NADPH,
another eNOS cofactor, for ROS production, compromising NO levels
(Drummond and Sobey, 2014). In addition, NOX activate redox-
sensitive transcriptional factors such as NF-κB and HIF1α, increasing
inflammation and hypoxia in the plaque (Diebold et al., 2012; Menden
et al., 2015). Based on those findings, NOX antagonists have been
developed for the treatment of cardiovascular diseases and are
currently in preclinical testing.
PFKFB3, a key activator of glycolysis (the main pathway source for
energy in EC), is highly expressed in proliferating ECs. Interestingly,
genetic or pharmacological inhibition of PFKFB3 impairs the ability of
ECs to sprout in vitro and to form vessels in vivo (De Bock et al., 2013a,
2013b; Schoors et al., 2014). Pharmacological PFKFB3 blockade, leads
to a partial and transient reduction of glycolysis, capable of reducing
pathological angiogenesis in inflamed skin, colon and eye disease,
without evoking systemic effects (De Bock et al., 2013a, 2013b). In
addition, overexpression of PFKFB3 overrules the pro-stalk cell effect
of Notch signaling, thereby making the stalk cell more competitive for
the tip position (Schoors, De Bock et al., 2014). Altogether, these
findings illustrate the pivotal role of glycolysis in angiogenesis and the
therapeutic potential of blocking glycolysis in plaque angiogenesis
inhibition.
6. Animal models
Among the different animal models used to study atherosclerosis,
pigs and rats are rarely suitable for exploring plaque neovascularization
in the atherosclerotic plaque because they seldom display plaque
neovessels (Van der Veken et al., 2016). In contrast, induced advanced
atherosclerotic plaques in the thoracic descending aorta of New
Zealand white rabbits show intra plaque angiogenesis, as detected
using contrast-enhanced ultrasound (Giannarelli et al., 2010).
Mice are a preferred model to study atherosclerosis since there are
all kinds of transgenic strains available. Unfortunately most of the
traditionally used strains, ApoE KO, LDLR KO and ApoE3*Leiden, do
not develop extensive neovessels in their atherosclerotic plaques.
Recently two models have been developed with atherosclerotic lesions
that are more unstable and prone to rupture.
One model is based on murine vein graft atherosclerosis. Human
atherosclerotic lesions in saphenous vein bypass grafts are vulnerable
and have a higher risk to disrupt than native atherosclerotic lesions (de
Vries et al., 2016; Yahagi et al., 2016). The murine vein graft model is
performed by the interposition of a caval vein from a donor mouse into
the carotid artery of an atherosclerosis prone recipient mouse.
Hypercholesterolemia in ApoE3*Leiden mice resulted in a significant
increase in accelerated atherosclerosis in vein grafts with profound vein
graft thickening within 4 weeks after surgery. These lesions are rich in
neovessels and are most likely formed through angiogenesis from the
vasa vasorum and consist of CD31 positive endothelial cells (de Vries
et al., 2012). In a substantial number of vein grafts, a considerable
amount of RBCs could be found in the extracellular matrix, adjacent to
the neovessels, suggesting leakiness and intraplaque hemorrhage
(Fig. 1). Foam cell accumulation was even observed within seven days
after vein bypass grafting, which illustrates the extreme fast initiation
of this accelerated atherosclerosis (Lardenoye et al., 2002). Reducing
inflammatory responses in this model could inhibit IPH, as well as
erosions and plaque dissection thereby increasing plaque stability
(Wezel et al., 2016).
Fig. 1. Plaque angiogenesis. Once in the plaque macrophages engulf oxLDL and become lipid filled foam cells. Their accumulation activates cytokine production that promotes the
influx of neutrophils, mast cells and monocytes. The high oxygen consumption of these inflammatory cells leads to hypoxia. HIF-1α and VEGF, together with an unbalanced presence of
the destabilizing factor Ang2 bound to its receptor Tie2, trigger the formation of leaky neovessels. (Magnification) Intraplaque hemorrhage, with extravasation of red blood cells and
inflammatory cells, is due to immature neovessels, lacking proper enveloping pericytes and poor tight junctions between endothelial cells. Macrophages accumulate cholesterol to the
point of becoming foam cells by phagocytizing extravasated red blood cells.
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Another example of animal model with spontaneous plaque rupture
is the ApoE KO Fbn1C1039G+/− mice model. A heterozygous mutation
C1039G+/− in the Fbn1 gene results in the fragmentation of elastic
fibers in the media of the vessel wall (Van der Veken et al., 2016). The
effect of increased arterial stiffness, due to progressive elastic fiber
degeneration, on atherosclerosis was studied in this model. ApoE KO
Fbn1C1039G+/− mice fed with a Western diet for 20 weeks, show sign
of plaque destabilization, such as increased number of fibrous caps and
enlargement of the necrotic core (Van Herck et al., 2009). The
atherosclerotic plaques of ApoE KO Fbn1C1039G+/− mice contained
highly leaky plaque neovessels and IPH, resulting in plaque rupture,
myocardial infarction, stroke, and sudden death (Van der Donckt et al.,
2015).
7. Conclusions
In this review we described the pathological processes associated
with angiogenesis in atherosclerotic plaques and illustrate how plaque
neovascularization and IPH are strongly correlated with atherosclerotic
plaque progression, instability and rupture (Fig. 2). The established
impact of plaque neovascularization on the evolution of atherothrom-
botic events, together with improved animal models and new imaging
technologies, provide a new basis for the development of anti-angio-
genic strategies to prevent atherosclerotic plaque progression and
instability.
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